The MRI guided neurosurgical ablation market is estimated to reach USD 168.13 million in 2024. It is estimated that revenue will increase at a CAGR of 3.1% between 2024 and 2034. The market is anticipated to reach USD 227.56 million by 2034.
MRI guided neurosurgical ablation is minimal invasive technique this is useful in the treatment of various medical conditions such as brain metastases, radiation necrosis, glioma, epilepsy, and other treatments. Drug resistant epilepsy is the most common indication for the treatment. With the ongoing development adoption of non-cooled laser systems is increasing.
Market players are focusing on achieving regulatory approval in multiple countries to increase their revenue stream. As the insurance companies are providing coverage for the procedure the demand for MRI guided neurosurgical ablation system increase. The combination for MRI guided neurosurgical ablation and drug therapy offers promising result for the patient.
MRI Guided Neurosurgical Ablation Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 163.14 million |
| Estimated Size, 2024 | USD 168.13 million |
| Projected Size, 2034 | USD 227.56 million |
| Value-based CAGR (2024 to 2034) | 3.1% |
The market for MRI-guided neurosurgical ablation is witnessing brisk growth primarily due to rising cases of drug-resistant epilepsy of approximately 11-41% among all cases of epilepsy. Conventional antiepileptic treatments fail in most cases, thereby creating huge demand for alternative interventions in the form of MRI-guided ablation.
This is a minimally invasive procedure involving real-time MRI imaging for targeting areas in the brain, that are characterized by epileptic foci, without causing major damage to adjacent portions.
The clinical studies established that laser interstitial thermal therapy significantly lowers the frequency of seizures by 60-70% and can become a promising treatment in future for patients who have fewer pharmaceutical choices.
Another advantage is growing preference towards minimally invasive procedures due to shorter recovery periods, less exposure to complications, and no scarring. Hospital stays for LITT are usually for a day or two, while patients undergoing traditional surgeries have to spend up to 5-7 days in the hospital.
Other factor include rising insurance coverage of MRI-guided procedures. As greater numbers of companies realize clinical effectiveness combined with higher long-term cost savings, access is eased. Indeed, recent moves by the major insurers indicate increased acceptance of MRI-guided interventions.
However, the high initial costs of acquiring and maintaining advanced MRI-guided technologies are a limitation to the market growth. It is too expensive for most small healthcare facilities and for those in developing regions. Despite such obstacles, growing necessity in appropriate treatments of refractory epilepsy continues to fuel interest in MRI-guided neurosurgical ablation.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The below table presents the expected CAGR for the global MRI guided neurosurgical ablation market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 4.2%, followed by a slightly lower growth rate of 3.8% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 4.2% (2023 to 2033) |
| H2 | 3.8% (2023 to 2033) |
| H1 | 3.1% (2024 to 2034) |
| H2 | 2.7% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 3.1% in the first half and remain relatively moderate at 2.7% in the second half. In the first half (H1) the market witnessed a decrease of 110 BPS while in the second half (H2), the market witnessed a decrease of 110 BPS.
Rising Incidence of Drug-Resistant Epilepsy has fueled the MRI Guided Neurosurgical Ablation Market growth
Drug Resistant epilepsy is characterized by the continuous seizure episode even after the treatment by antiepileptic drugs. Since the traditional treatment fail to stop seizure episode there is need for alternative method such as MRI-guided ablation.
MRI-guided neurosurgical ablation is a minimal invasive procedure used for drug-resistant epilepsy. Real-time MRI imaging makes accurate delivery of ablation possible, targeting only the epileptic tissue of the brain. It reduced the damage to the surrounding area. This is particularly beneficial for the treatment of deep-seated foci in the brain or other inaccessible locations due to anatomical constraints in drug-resistant epilepsy patients.
Clinical studies reflect an advanced outcome for patients with drug-resistant epilepsy. For example, the capability of LITT to reduce seizures as high as 60-70% in cases makes this one promising treatment option for patients running out of pharmaceutical options. With every additional drug-resistant epilepsy case, healthcare providers seek to utilize more advanced techniques for the improvement of the patient outcome and quality of life.
One of the more common reasons for applying MRI-guided neurosurgical ablation is the increasingly diagnosed incidence of drug-resistant epilepsy, which comprises approximately 11-41% of all epilepsies. Hence, all the aforementioned factor contributes to the market growth.
Increased Preference for Minimal Invasive Procedures drives demand for MRI Guided Neurosurgical Ablation
Minimally invasive procedures work in favor of the patient, mainly because of reduced recovery time, lowered risk of complications, and minimal scarring, and has gained tremendous momentum in modern healthcare. This is specifically pertinent to neurosurgery, because precision and minimal damage to surrounding brain tissue are critical.
MRI-guided neurosurgical ablation, particularly LITT, is among the leaders of this new wave. It enables surgeons to make highly targeted interventions within the brain under real-time imaging using MRI while ablating offending tissue without significant disruption to intact areas.
Patients stay for less time in the hospital, recover speedily, and have fewer complications following surgery. For instance, the studies have demonstrated that LITT procedures normally require a 1 to 2 day hospital stay; however, conventional procedures normally take up to 5 to 7 days.
There is an increasing need for minimally invasive procedures in this arena, especially concerning neurological disease treatment, where high accuracy and precision are required. Patients will shift more towards MRI-guided ablation because of the advantages it brings about, like reduced trauma and fast recovery, which fuel acceptance of such technologies in neurosurgery.
The growing and aggressive demand for MIS is therefore a significant driving force for the market demand for MRI-guided neurosurgical ablation of neurological disorders such as epilepsy, brain tumors, and movement disorders.
Expanding Insurance Coverage for MRI-guided neurosurgical ablation procedures provides an Opportunity for Market Growth
Expanding insurance coverage for MRI-guided neurosurgical ablation procedures is increasing growth opportunities within the market. As more insurance companies start acknowledging the clinical efficacy and eventual long-term savings of such minimally invasive treatments, more patients and healthcare institutions are being facilitated in accessing better technology such as MRI-guided focused ultrasound (MRgFUS) and laser ablation therapies, thus eradicating the barriers that have traditionally limited such procedures' wide adoption.
In February 2024, Anthem Blue Cross and Blue Shield (BCBS) announced coverage for the innovative focused ultrasound pallidotomy procedure. This follows a January 2024 announcement from Insightec, stating that approximately 9.5 million members of the USA military and their dependents under Tricare would receive reimbursement for treating essential tremor with focused ultrasound.
Additionally, in November 2023, Monteris Medical revealed that Aetna had updated its medical policy. This update extends coverage to beneficiaries affected by recurrent brain metastases, radiation necrosis, and recurrent glioblastoma. The inclusion of insurance coverage for MRI-guided neurosurgical ablation procedures is expected to enhance adoption rates among healthcare providers, as it lowers financial barriers for patients.
High Initial Costs of Equipment and Procedures Hinder the Market Growth
Highly advanced, minimally invasive MRI-guided technologies are MRI-guided focused ultrasound (MRgFUS) and laser interstitial thermal therapy (LITT). Such systems are expensive to acquire, install, and maintain, and therefore may be unaffordable for medium and small healthcare facilities as well as those located in developing regions.
Having MRI technology in place is a prerequisite for adopting the MRI-guided procedure. This limits the number of potential customers who may embrace the equipment. Not to mention, the MRI Machine is an expensive one on its cost. Apart from the MRI equipment itself, specific ablation systems such as focused ultrasound or laser ablation devices add an even further cost burden on the top.
These systems are based on MRI hardware and software combinations, which demands complex hardware and software integration for functionality in unison with the MRI machines, making them costly altogether. Moreover, they usually demand one of the specialized operating rooms, known as MRI-compatible surgical suites, which also adds extra cost due to the need for infrastructure changes.
The maintenance costs for MRI-guided systems are also high. It is a must to service the MRI machines and ablation devices annually to ensure that these instruments function accurately and give out the results correctly. Hence higher equipment and procedure costs restrain the growth of the MRI-guided neurosurgical ablation market.
Principal Consultant
The MRI guided neurosurgical ablation industry recorded a CAGR of 2.3% between 2019 and 2023. According to the industry, MRI guided neurosurgical ablation generated USD 163.14 million in 2023, up from USD 148.80 million in 2019.
Traditionally, this market was associated with limited adoption, due to technological limitations and the procedural expense. Things changed when MRI-guided LITT, at the early 2000s, came to become the first therapy to enter the space of brain tumors and epilepsy to prove that the minimally invasive approaches were indeed feasible. There was gradual growth as healthcare providers began recognizing the benefits of MRI guidance in enhancing surgical precision and patient outcomes.
Currently, the market is experiencing robust growth due to the growing prevalence of neurological disorders, including brain tumors. There is a strong trend towards minimally invasive surgical techniques primarily because of developments in MRI technology where the current imaging is more real-time and procedures are accurate. Brain health awareness, which is also growing, and the higher acceptability of insurance reimbursement has been resulting in an increasing number of hospitals adopting these technologies.
Future innovations in the market are supposed to include incorporation of artificial intelligence towards better treatment planning and outcomes. The development of high-intensity focused ultrasound (HIFU) devices is anticipated to expand treatment options. With the rise patient centric care the market for MRI guided neurosurgical ablation is expected to increase.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 65.6% in global market. These market leaders are distinguished by their consumer base. They provide a state of the art manufacturing of medical device utilizing the latest technology and meeting the regulatory standards providing the highest quality. Prominent companies within tier 1 include Medtronic plc.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 32.3% market share. These are characterized by a strong presence overseas and strong market knowledge. These market players have good technology and ensure regulatory compliance but may not have advanced technology and global reach. Prominent companies in tier 2 include Insightec and Monteris Medical Inc. etc.
Finally, Tier 3 companies, has limited market presence. These companies are improving the local presence and establishing partnership with distributor within other country to increase their global presence as well.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the MRI guided neurosurgical ablation market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East and Africa (MEA), is provided. The United States is anticipated to remain at the forefront in North America through 2034 in terms of market size. India is projected to witness a CAGR of 5.6% from 2024 to 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| USA | 2.2% |
| Canada | 2.3% |
| Germany | 3.2% |
| France | 3.2% |
| Italy | 2.8% |
| China | 3.9% |
| India | 5.6% |
| Japan | 3.8% |
Advanced treatment options are in huge demand because of increased neurological disorders. According to the 2023 data from American Cancer Society, there were nearly 25,400 new cases of malignant tumors of the brain or spinal cord. This underlines the critical need for effective intervention methods.
The United States also has a good health system that would allow minimally invasive procedures such as MRI-guided laser ablation to be carried out. This method not only reduces postoperative pain but it also shortens the periods of recovery compared to conventional surgery.
Also United States is characterized by the leadership of prime medical device manufacturer who invests in R&D in order to speed up the innovation of advanced ablation systems that increase procedural safety and efficiency. The above factors along with the availability of highly skilled neurosurgeons and a well-established network of hospitals specializing in neurosurgery contributes to the market's expansion.
Germany operated on dual health insurance system that features both statutory health insurance (SHI) and private health insurance (PHI), resulting in majority of population being covered, which provides access to the wide range of technological advancements available today in most hospitals and clinics for better treatments.
Apart from this, the German healthcare sector focuses on quality delivery of care to patients. In such a respect, the Federal Joint Committee is obligated to regulate services delivered for evidence-based treatments. Also, it verifies if such delivered treatments are in compliance with the set quality standards. Such a regulatory environment increases the trust within new technologies, which makes healthcare providers prepared to accept MRI-guided ablation techniques.
Minimally invasive surgical options form the core focus of these preferences as recovery periods have diminished and risks associated with traditional surgeries have also reduced. Hence the aforementioned factor have fueled the German MRI guided neurosurgical ablation market.
Japan has a high percentage of aging population, which increases the incidence of neurological disorders. The country has high life expectancy for most people around the world. This results in a larger elderly demographic that is prone to glioblastoma, Alzheimer’s, Parkinson’s etc. As the prevalence of glioblastoma grows, the demand for effective treatment options also goes up, especially including minimally invasive surgeries such as MRI-guided laser ablation.
The demand for these advance treatment is increasing with the growing elderly population. In addition, the good health care system in Japan enables it to utilize new technology in healthcare.
MRI guided neurosurgical ablation enhances healthcare quality while a culture emphasizes good health care, raising the acceptance of patients toward it as well as their demand for innovative treatments. Furthermore, a push of Japan towards medical technology research and development gives a positive view of MRI-guided neurosurgical ablation growth.
A description of the leading segments in the industry is provided in this section. The epilepsy segment held 50.9% of the value share in 2024. Based on the end user, hospitals held 43.4% of the market in 2024.
| Treatment Type | Epilepsy |
|---|---|
| Value Share (2024) | 50.9% |
The growing number of patients are being diagnosed with epilepsy. The total diagnosed cases have crossed over millions worldwide necessitates effective treatment options. According to the World Health Organization, 50 million people worldwide suffer from epilepsy. Each year, 5 million people are diagnosed worldwide with epilepsy annually. In developed countries, the 49 per 100,000 people are diagnosed with epilepsy each year.
Risk factors such as brain tumor, head injury, drug abuse, alcoholism, brain infection, etc contributed to epileptic conditions. Apart from this, certain forms of epilepsy can be best treated using MRI-guided ablation techniques as it allow for maximum accuracy in directly targeting the specific part of the brain tissue responsible for seizures so that damage to other parts could be greatly minimized.
These procedures became more acceptable among neurologists and neurosurgeons. This has led to increasing number of MRI guided neurosurgical ablation procedures being performed for epileptic conditions, making it the dominating treatment type.
| End User | Hospitals |
|---|---|
| Value Share (2024) | 43.4% |
Hospitals the main cornerstone of the healthcare infrastructure. They are the primary center for disease evaluation, diagnosis and treatment. Hence it experience the highest number of patient visit for various disease condition including the neurological conditions.
Also the total number of hospitals establishment are far greater than any other healthcare institutions. Hence, the high patient footfall and wide presence make hospital the dominant end user for MRI guided neurosurgical ablation systems.
The presence of skilled neurosurgeons in hospitals ensure quality care, making minimally invasive procedure effective. Hospitals are well-positioned to handle the growing demand for neurological disorders treatment. They are able to provide comprehensive care from diagnosis to post-operative recovery.
Which makes them the preferred choice for patients seeking effective solutions. Also, the widespread presence of hospitals ensures that patients have access to necessary treatments. Their established reputation for delivering high-quality healthcare contributes to their continued dominance
Industry leader have a strong focus on research and development. The MRI guided neurosurgical ablation systems are constantly being updated with new functionality surpassing its predecessors.
Since the MRI guided neurosurgical procedures are cost intensive, market players are striving to get insurance coverage for the procedures. This would increase number of procedures performed and hence result in high demand for MRI guided neurosurgical ablation systems driving the company’s revenue.
Recent Industry Developments in the MRI Guided Neurosurgical Ablation Market
In terms of product, the industry is segmented into MRI guided laser therapy systems, MRI guided focused ultrasound systems, and accessories.
In terms of treatment types, the industry is bifurcated into brain metastases, radiation necrosis, glioma, epilepsy, and other treatments.
In terms of end use, the industry is segregated into hospitals, cancer treatment centers, specialized surgical centers (neurology and neurosurgery centers), and academic & research institutes.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, the Middle East, and Africa have been covered in the report.
MRI guided neurosurgical ablation industry is expected to increase at a CAGR of 3.1% between 2024 and 2034.
The MRI guided laser therapy systems segment is expected to occupy a 30.6% market share in 2024.
The market for MRI guided neurosurgical ablation is expected to reach USD 227.6 million by 2034.
The United States is forecast to see a CAGR of 2.2% during the assessment period.
The key players in the MRI guided neurosurgical ablation industry include Medtronic plc, Insightec, Monteris Medical Inc., and ClearPoint Neuro, Inc.
Explore Healthcare Insights
View Reports
MRI Guided Neurosurgical Ablation Market
